Xu Y, Casey G, Mills G B
Department of Cancer Biology, Cleveland Clinic Foundation, Ohio 44195, USA.
J Cell Physiol. 1995 Jun;163(3):441-50. doi: 10.1002/jcp.1041630303.
Lysophospholipids have recently been demonstrated to induce activation and proliferation of fibroblasts and other cell lineages by interacting with high affinity cell surface receptors leading to specific intracellular signaling events. Platelet activation, likely at the site of injury or inflammation, results in increased production of lysophospholipids suggesting a possible source of lysophospholipids. We have recently demonstrated that high concentrations of lysophospholipids are present in ascites and plasma from ovarian cancer patients, suggesting that physiologically produced lysophospholipids could interact with cells present in these fluids, including lymphocytes, and alter their function. We demonstrate herein that lysophosphatidic acid (LPA), lysophosphatidylserine (LPS), and sphingosylphosphorylcholine (SPC) activate the Jurkat T cell line. Each of the lysophospholipids induced a transient increase in cytosolic free calcium ([Ca2+]i) in Jurkat cells. Increases in [Ca2+]i were cross-desensitized by LPA, LPS and SPC, suggesting that the lysophospholipids share the same receptor(s) or that their downstream signaling pathways converge or interact. Lysophosphatidylglycerol (LPG), a competitive inhibitor of the putative LPA receptor, inhibited the calcium releasing activity of LPA, but not that of LPS and SPC, suggesting that these lysophospholipids interact with different receptors and that desensitization is due to interactions in downstream signaling pathways. The ability of the lysophospholipids to induce increases in [Ca2+]i was attenuated, but not completely blocked, by increases in [Ca2+]i induced by activation of the thrombin receptor. In contrast, increases in [Ca2+]i induced by the lysophospholipids and cross-linking the CD3 component of the T cell receptor complex with the UCHT1 antibody did not undergo heterologous desensitization. Strikingly, LPA is sufficient to stimulate proliferation of Jurkat cells in serum-free medium or in synergy with low concentrations of fetal bovine serum. In addition, LPA also increased the production of the T cell growth factor, interleukin 2 (IL-2), by Jurkat cells treated with phorbol esters. LPS, in contrast, inhibited Jurkat proliferation while increasing IL-2 production and SPC inhibited both processes. Thus, although all three lysophospholipids were sufficient to induce a transient increase in [Ca2+]i in Jurkat cells, they induced markedly different physiological consequences.
溶血磷脂最近已被证明可通过与高亲和力细胞表面受体相互作用,引发特定的细胞内信号事件,从而诱导成纤维细胞和其他细胞谱系的激活与增殖。血小板激活可能发生在损伤或炎症部位,会导致溶血磷脂生成增加,这表明溶血磷脂可能存在一个来源。我们最近证明,卵巢癌患者的腹水和血浆中存在高浓度的溶血磷脂,这表明生理产生的溶血磷脂可能与这些液体中的细胞(包括淋巴细胞)相互作用,并改变其功能。我们在此证明,溶血磷脂酸(LPA)、溶血磷脂酰丝氨酸(LPS)和鞘氨醇磷酸胆碱(SPC)可激活Jurkat T细胞系。每种溶血磷脂均能诱导Jurkat细胞胞质游离钙([Ca2+]i)短暂升高。LPA、LPS和SPC可使[Ca2+]i的升高发生交叉脱敏,这表明这些溶血磷脂共享相同的受体,或者它们的下游信号通路汇聚或相互作用。溶血磷脂酰甘油(LPG)是假定的LPA受体的竞争性抑制剂,可抑制LPA的钙释放活性,但不能抑制LPS和SPC的钙释放活性,这表明这些溶血磷脂与不同的受体相互作用,且脱敏是由于下游信号通路中的相互作用所致。凝血酶受体激活诱导的[Ca2+]i升高会减弱溶血磷脂诱导[Ca2+]i升高的能力,但不会完全阻断。相反,溶血磷脂诱导的[Ca2+]i升高以及用UCHT1抗体使T细胞受体复合物的CD3成分交联所诱导的[Ca2+]i升高并未发生异源脱敏。引人注目的是,LPA足以在无血清培养基中或与低浓度胎牛血清协同作用下刺激Jurkat细胞增殖。此外,LPA还可增加经佛波酯处理的Jurkat细胞产生T细胞生长因子白细胞介素2(IL-2)的量。相比之下,LPS抑制Jurkat细胞增殖,同时增加IL-2的产生,而SPC则抑制这两个过程。因此,尽管所有三种溶血磷脂都足以诱导Jurkat细胞中[Ca2+]i短暂升高,但它们会引发明显不同的生理后果。